In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model

In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model

IgE monoclonal antibodies hold great potential for cancer therapy. Preclinical in vivo systems, particularly those in which the antibody recognizes the host species target antigen and binds to cognate Fc receptors, are often the closest approximation to human exposure and represent a key challenge f...

Full description

Bibliographic Details
Main Authors: Iwan P. Williams, Silvia Crescioli, Heng Sheng Sow, Heather J. Bax, Carl Hobbs, Kristina M. Ilieva, Elise French, Giulia Pellizzari, Vivienne Cox, Debra H. Josephs, James F. Spicer, Sophia N. Karagiannis, Silvia Mele
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:mAbs
Subjects:
IgE
rat model
immunotherapy
allergooncology
CSPG4
antibody
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2019.1685349

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2019.1685349

Similar Items